Jubilant Life resolves FDA raised issues for Montreal facility

Jubilant Life Sciences Ltd, an integrated pharmaceuticals and life sciences company, today announced successful resolution of USFDA warning letter for its Montreal facility.

We have received a communication from the US Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada, as 'Acceptable'.

This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications, a statement issued here said.

The development follows completion of FDA's review of the company's responses post the February letter and the subsequent re-inspection conducted at Jubilant's Montreal facility in September 2013. This development successfully resolves the FDA issues at our Montreal facility, it said.

Jubilant Life Sciences is engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients.

It also provides services in contract manufacturing and drug discovery and development. The company has 10 manufacturing facilities in India, US and Canada and a team of over 6,300 people across the globe.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India’s festivals teach us to share our wealth and joy

    India is an aporia in its own true sense.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Sustainable model for rural sanitation

Prime minister Narendra Modi has promised to build a toilet ...

Zehra Naqvi

How smells evoke strong memories

Remember that time when a passing fragrance transported you to ...

Dharmendra Khandal

Indian zoos need a fresh approach

Recently, when a man jumped in a tiger trench of ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture